Convalescent plasma in Covid-19 : Possible mechanisms of action
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved..
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Autoimmunity reviews - 19(2020), 7 vom: 27. Juli, Seite 102554 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rojas, Manuel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ACE-2 receptor |
|---|
| Anmerkungen: |
Date Completed 10.06.2020 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.autrev.2020.102554 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309635950 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309635950 | ||
| 003 | DE-627 | ||
| 005 | 20231225134342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.autrev.2020.102554 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM309635950 | ||
| 035 | |a (NLM)32380316 | ||
| 035 | |a (PII)S1568-9972(20)30116-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rojas, Manuel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Convalescent plasma in Covid-19 |b Possible mechanisms of action |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.06.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ACE-2 receptor | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Convalescent plasma | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a Intravenous immunoglobulins | |
| 650 | 4 | |a Neutralizing antibodies | |
| 650 | 4 | |a SARS-Cov-2 | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Rodríguez, Yhojan |e verfasserin |4 aut | |
| 700 | 1 | |a Monsalve, Diana M |e verfasserin |4 aut | |
| 700 | 1 | |a Acosta-Ampudia, Yeny |e verfasserin |4 aut | |
| 700 | 1 | |a Camacho, Bernardo |e verfasserin |4 aut | |
| 700 | 1 | |a Gallo, Juan Esteban |e verfasserin |4 aut | |
| 700 | 1 | |a Rojas-Villarraga, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez-Santana, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz-Coronado, Juan C |e verfasserin |4 aut | |
| 700 | 1 | |a Manrique, Rubén |e verfasserin |4 aut | |
| 700 | 1 | |a Mantilla, Ruben D |e verfasserin |4 aut | |
| 700 | 1 | |a Shoenfeld, Yehuda |e verfasserin |4 aut | |
| 700 | 1 | |a Anaya, Juan-Manuel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Autoimmunity reviews |d 2002 |g 19(2020), 7 vom: 27. Juli, Seite 102554 |w (DE-627)NLM126096996 |x 1873-0183 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2020 |g number:7 |g day:27 |g month:07 |g pages:102554 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.autrev.2020.102554 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2020 |e 7 |b 27 |c 07 |h 102554 | ||